Hepatosplenic T-cell lymphoma: the decisions you may face

Cancer page →Second-opinion finder →

1 treatment setting, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

All cases

2 optionsCompare side by side →

Intensive platinum- and cytarabine-based induction rather than CHOP, then allogeneic or autologous transplant in first remission for fit patients.

The options, in plain words

CytarabineApprovedPyrimidine nucleoside analogue (antimetabolite)

Cytarabine is the core chemotherapy for acute myeloid leukaemia, given with an anthracycline as the classic 7+3 induction and at high doses for consolidation; it is also injected into the spinal fluid to treat or prevent leukaemia in the brain.

CisplatinApprovedCytotoxic chemotherapy (platinum)

Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.

Also referenced:Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)Allogeneic stem cell transplant (allo-SCT)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Cisplatin all recorded rates →

Dose reduce or avoid for CrCl below 60 (carboplatin is the alternative).

Questions to ask about this decision

Between Cytarabine and Cisplatin, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (all cases), which of the standard options do you recommend and why?
Why: Guideline options include: Intensive platinum- and cytarabine-based induction rather than CHOP, then allogeneic or autologous transplant in first remission for fit patients.
Am I a candidate for Cytarabine, Cisplatin, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care